TG Therapeutics raised 2026 global revenue guidance to $1 billion after reporting about $260 million in third-quarter revenue, including $233 million in U.S. BRIUMVI net revenue. The shares rose 5.9% after earnings.
Shares dropped 6.3% following the quarter as investors reacted negatively to a cautious outlook and the implied challenges expanding beyond the core BRIUMVI IV franchise, despite steady commercial execution and pipeline progress.
TG Therapeutics reported robust Q3 2025 results, highlighted by impressive sales growth for BRIUMVI, which continues to outperform market expectations. The company remains committed to innovation and disciplined financial management.